{
  "Variants Include": [
    {
      "Gene": "PARK2",
      "variants": [
        {
          "HGVS": "N.D.",
          "cDNA Change": {
            "transcript": "N.D.",
            "ref": "N.D.",
            "alt": "N.D.",
            "position": "N.D."
          },
          "Protein Change": {
            "ref": "N.D.",
            "alt": "N.D.",
            "position": "N.D."
          },
          "Description in input context": "Familial parkin mutations that either abolish or preserve ligase activity"
        }
      ]
    }
  ],
  "Described Disease": {
    "Described Disease": "Autosomal Recessive Juvenile Parkinson’s Disease (AR-JP)",
    "MONDO": "MONDO:0011571"
  },
  "Experiment Method": [
    {
      "Assay Method": "Chromatin Immunoprecipitation (ChIP)",
      "Material used": {
        "Material Source": "Cell line and animal model",
        "Material Name": "Fibroblasts and mouse brains",
        "Description": "ChIP experiments were performed to analyze parkin's interaction with the p53 promoter in fibroblasts and mouse brains."
      },
      "Readout type": "Quantitative",
      "Readout description": [
        {
          "Variant": "N.D.",
          "Conclusion": "Pathogenic mutations abolish DNA binding and promoter transactivation",
          "Molecular Effect": "Loss of function",
          "Result Description": "Pathogenic parkin mutations disrupt DNA binding to the p53 promoter and impair transactivation."
        }
      ],
      "Biological replicates": {
        "Biological replicates": "N.D.",
        "Description": "Not explicitly described in the text."
      },
      "Technical replicates": {
        "Technical replicates": "N.D.",
        "Description": "Not explicitly described in the text."
      },
      "Basic positive control": {
        "Basic positive control": "N.D.",
        "Description": "Not explicitly described in the text."
      },
      "Basic negative control": {
        "Basic negative control": "N.D.",
        "Description": "Not explicitly described in the text."
      },
      "Validation controls P/LP": {
        "Validation controls P/LP": "N.D.",
        "Counts": "N.D."
      },
      "Validation controls B/LB": {
        "Validation controls B/LB": "N.D.",
        "Counts": "N.D."
      },
      "Statistical analysis method": {
        "Statistical analysis method": "N.D."
      },
      "Threshold for normal readout": {
        "Threshold for normal readout": "Protein/DNA binding and transactivation levels consistent with wild-type parkin",
        "Source": "Custom"
      },
      "Threshold for abnormal readout": {
        "Threshold for abnormal readout": "Significant reduction in DNA binding or transactivation compared to wild-type parkin",
        "Source": "Custom"
      },
      "Approved assay": {
        "Approved assay": "Yes"
      }
    },
    {
      "Assay Method": "Overexpression and Depletion Studies",
      "Material used": {
        "Material Source": "Cell line and animal model",
        "Material Name": "Fibroblasts and mouse brains",
        "Description": "Overexpression and depletion experiments were conducted in fibroblasts and mouse brains to assess parkin's functional impact on p53."
      },
      "Readout type": "Quantitative",
      "Readout description": [
        {
          "Variant": "N.D.",
          "Conclusion": "Pathogenic mutations impair parkin's transcriptional regulation of p53",
          "Molecular Effect": "Loss of function",
          "Result Description": "Depletion of parkin or introduction of pathogenic mutations led to dysregulated p53 activity."
        }
      ],
      "Biological replicates": {
        "Biological replicates": "N.D.",
        "Description": "Not explicitly described in the text."
      },
      "Technical replicates": {
        "Technical replicates": "N.D.",
        "Description": "Not explicitly described in the text."
      },
      "Basic positive control": {
        "Basic positive control": "N.D.",
        "Description": "Not explicitly described in the text."
      },
      "Basic negative control": {
        "Basic negative control": "N.D.",
        "Description": "Not explicitly described in the text."
      },
      "Validation controls P/LP": {
        "Validation controls P/LP": "N.D.",
        "Counts": "N.D."
      },
      "Validation controls B/LB": {
        "Validation controls B/LB": "N.D.",
        "Counts": "N.D."
      },
      "Statistical analysis method": {
        "Statistical analysis method": "N.D."
      },
      "Threshold for normal readout": {
        "Threshold for normal readout": "p53 activity within 80–120% of wild-type levels",
        "Source": "Custom"
      },
      "Threshold for abnormal readout": {
        "Threshold for abnormal readout": "p53 activity < 80% or > 120% of wild-type levels",
        "Source": "Custom"
      },
      "Approved assay": {
        "Approved assay": "Yes"
      }
    }
  ]
}